Delivery Order SPE2DB24D9223-SPE2DB24FKDZE

Award Date 7/18/24
Potential Completion Date 7/19/24
Potential Value $6.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $27,477.72 firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the supply of MENVEO 1 VIAL-A-C-Y-W-135-DIP 0.5ML vaccines, with an ultimate completion date of August 7, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB...
This is a $1,080.93 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of the MENVEO VACCINE VL 5S medical product, with an ultimate completion date of June 17, 2025. DMS Pharmaceutical Group Inc. has a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a total ceiling value of $1,169.37 and provides for the delivery of a variety of pharmaceutical products, including meningococcal group vaccines, to defense medical facilities worldwide. The contract is a firm fixed-price delivery order awarded under DMS Pharmaceutical Group's...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $12,676.34, is for the delivery of MENVEO 1 VIAL-A-C-Y-W-135-DIP 0.5ML, a vaccine product. The contract has an ultimate completion date of May 8, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of meningococcal group vaccines and other pharmaceutical products, with a ceiling value of $25,221.70. The contract is a firm fixed-price purchase order, with a completion date of May 19, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of MENVEO A-C-Y-W vaccines, with a ceiling value of $3,603.10 and a period of performance through April 2025. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,112.04 firm fixed-price delivery order covers the supply of the Menveo vaccine. The contract is not associated with any set-aside designations. It is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This...
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $1,080.93 firm fixed-price delivery order is for the supply of MENVEO A-C-Y-W KIT (2 VIALS), with a period of performance through May 22, 2025. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which covers a wide range of...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $8,457.90, is for the delivery of Menveo A-C-Y-W Kits, which are specialized pharmaceutical products. The contract is a firm fixed-price delivery order and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite...
This federal contract award, with ID SPE2DB20D6037|SPE2DB24FTXC4, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,538.59 firm fixed-price delivery order is for MENVEO A-C-Y-W KIT (2 VIALS)S, which the company will supply to support the recurring medical supply needs of military health facilities worldwide. The award is part of a larger indefinite delivery contract (IDC)...
  • SPE2DB24D9223
    Indefinite Delivery Contract
  • SPE2DB24D9223-SPE2DB24FKDZE
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,755.50 award is under the DLA's SPE2DB24 indefinite delivery contract (IDC), which has a ceiling value of up to $499,999,999 and runs through December 31, 2025. This IDC allows the DLA to issue delivery orders for a wide range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical supplies, to fulfill the recurring medical needs of Department of Defense (DoD) healthcare facilities worldwide. The current award is for Menveo, a meningococcal vaccine, with a completion date of July 19, 2024. This contract has no set-aside designation.

Generated 10/23/24, 9:12 AM